Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients

Thrombosis and Haemostasis

Volumn 76, Issue 6, 1996, Pages 939-943

  Boneu, B ^a   Destelle, G ^b  

^a CHU PURPAN   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; TICLOPIDINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0030457556     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650689     Document Type: Article

References (12)

1. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 2: 180-98.
2. Mills DCB, Puri R, Hu CJ, Minnity C, Grana G, Freedman MD, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 2: 430.
3. 3H]-2 methylthio ADP to rat platelets. Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-7.
4. Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 9: 434-44.
5. Gachet C, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes. An effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost 1992; 68: 79-83.
6. Dunn FW, Soria J, Soria C, Thomaidis A, Lee H, Coeur JP. In vivo effects of ticlopidine on fibrinogen platelet cofactor activity and binding of fibrinogen on platelets. Agents Actions 1984; 15: 97-103.
7. Kieffer G, Caplain H, Thiercelin JF, Thebault JJ. Tolerance and pharmacological activity of a new antiplatelet agent clopidogrel (SR 25990 C) in normal healthy volunteers after single increasing administrations. Thromb Haemost 1989; 62: 411 (abst).
8. Caplain H, Kieffer G, Thiercelin JF, Thebault JJ. Tolerance and clinical pharmacology of repeated administration of clopidogrel (SR 25990 C) a new antiplatelet agent, at three dose levels in normal healthy volunteers. Thromb Haemost 1989; 62: 410 (abst).
9. Beker F. La classification de l'insuffisance arterielle des membres inférieurs de Leriche et Fontaine une réactualisation nécessaire. Méd et Hyg 1991; 49: 143-9.
10. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous venostasis bleeding time technique. J Lab Clin Med 1941; 26: 1812-22.
11. Mass WK, Easton JD, Adams HP. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. NEJM 1989; 321: 501-7.
12. Molony B, Analysis of the side effects of ticlopidine in ticlopidine, platelets and vascular disease. HassWK, Donald Easton J (eds). New York: Springer Verlag 1993, pp 117-39.